Business Wire

Shippeo Announces Anand Medepalli as Chief Product Officer

14.12.2021 11:00:00 EET | Business Wire | Press release

Share

Shippeo, a global leader and European specialist in real-time transportation visibility, has announced the appointment of Anand Medepalli as their Chief Product Officer to lead the company during a time of immense growth and support clients with an innovative vision of Shippeo’s product offering.

Anand has over 25 years of experience as a trusted advisor with leading companies in product strategies, commercial account strategies, and asset planning decisions in transportation, supply chain, and financial services. He has spent much of his career advising companies and defining innovative solutions to drive their growth. Before Shippeo, Anand was Head of AI Solutions at ServiceNow, following the acquisition of Element AI, where he was Head of Products. Previous to this experience, Anand worked for several years at Blue Yonder, as the VP of Retail Planning products.

"One look around and you know that supply chains are under stress. Shippers, carriers, and LSPs need unprecedented visibility into their supply chains to serve their customers, and they need solutions that give them accurate insights into their operations,” says newly appointed Chief Product Officer, Anand Medepalli. “Shippeo, with its right vision and impressive technology, is addressing this problem head-on for some very innovative and well-known customers, and delivering significant value to them. It was a no-brainer for me to join the talented Shippians as I understood that this was where I could indulge in my passion for supply chain, big data, machine learning and AI in one place and at the same time make a significant positive difference to our customers."

With over 100 customers, including global brands like Coca-Cola HBC, Faurecia, and Total, Shippeo offers a best-in-market ETA prediction in terms of accuracy and reliability as well as a more granular degree of multimodal tracking, right down to handling unit and goods levels, which supports all modes of transport including ocean, road, LTL and FTL. Shippeo's ambition is to be the leading supply chain operating system, enabling fully automated and sustainable supply chains across the world.

Lucien Besse, Shippeo’s Chief Operating Officer, welcomes Anand to the team. “We are thrilled to welcome Anand to the Shippeo executive leadership team. He brings great skills at the intersection of product strategy, AI, machine learning, and supply chain management to the company”, said Besse. “As the Chief Product Officer, he will set the product strategy to disrupt the supply chain visibility marketplace with innovative solutions, playing a key role in the company’s development and continued success. His intimate knowledge and experience within the market are invaluable, and he will no doubt be a great asset within our leadership team.”

More information

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Celine Bonniot, Field Marketing Director, Shippeo, celine.bonniot@shippeo.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye